Novel medication strategies targeting brain mechanisms in pediatric ocd
This study aims to determine whether adding a medication called minocycline to
antidepressant treatment can help reduce symptoms of OCD. This study also aims to
learn more about the brains of children and adolescents with OCD.
Your child must be taking a stable dose of a serotonin reuptake inhibitor (SRI) in order to
participate in this study. During the 12 week study period, your child will continue to
take the SRI s/he is currently taking. Your child will also be given another medicine to
take which will be either minocycline or pill placebo (a pill with no medicine in it). There
is a two out of three chance that your child will receive minocycline instead of placebo.
You, your child, and the study doctor will not know whether your child is receiving
minocycline or placebo until after the study is over, but the information will be available
in case of a medical emergency.
Participants will be compensated for their participation. After the study period, follow-up
care including medication management will be provided for three additional months at no
cost to you.
• 8 - 20 years
• Genders: both
• Key inclusion criteria: Primary diagnosis of OCD and currently on a stable and adequate dose of an SRI
Your child may be eligible to participate in this study if he/she is diagnosed with Obsessive-Compulsive Disorder.
• Lifetime diagnosis of: psychotic disorder, bipolar disorder, eating disorder, pervasive developmental disorder, mental retardation, or substance/alcohol dependence
• Current diagnosis of major depressive disorder, attention-deficit hyperactivity disorder (ADHD), Tourette’s/Tic Disorder, or substance/alcohol abuse
• Diagnosis of pediatric autoimmune neuropsychiatric disorders associated with streptococcus (PANDAS)
• Active Suicidal Ideation
• Hoarding as the primary OCD symptom
• Pregnant, nursing, or planning to become pregnant